The Indian Council of Medical Research will conduct a survey from next week to examine the effectiveness of AstraZeneca's Covishield and Bharat Biotech's Covaxin in preventing the progression of Covid into a severe form.
URL copied
Bharat Biotech expects EUL from WHO for Covaxin in July- September
Bharat Biotech on Tuesday said it expects approval for its COVID-19 vaccine Covaxin from the World Health Organisation for Emergency Use Listing (EUL) during July-September. The company said regulatory approvals for Covaxin are in process in more than 60 countries including the USA, Brazil
and Hungary among others. Application for EUL has been submitted to WHO-Geneva. Regulatory approvals are expected during July-September 2021, it said in a release.
Emergency Use Listing (EUL) is a procedure to streamline the process by which new or unlicensed products can be used during public health emergencies, according to WHO guidelines.
Do gaj se zyada zaruri: What top scientific officer advises to crush Covid-19
Do gaj se zyada zaruri: What top scientific officer advises to crush Covid-19
The Covid-19 safety protocol has been tweaked in the latest advisory by the office of the Principal Scientific Advisor to Government of India. It now says SARS-CoV-2, the coronavirus that causes Covid-19, can be airborne for up to 10 metres.
advertisement
UPDATED: May 24, 2021 17:27 IST
Besides the usual focus on universal mask-wearing and regular hand washing, the new advisory emphasises a lot on indoor ventilation. (File photo)
Wearing a face mask, following hand hygiene, and keeping a two-metre social distance have been part of the standard Covid-19 safety protocol popularised by a government advertisement saying “do gaj doori, mask hai zaroori”.
The Hyderabad-based Bharat Biotech Ltd is confident about obtaining WHO s emergency use listing.
Hyderabad-based Bharat Biotech has submitted 90 per cent of documents to World Health Organisation (WHO) for obtaining emergency use listing for the Covaxin, according to sources.
The remaining documents are expected to be submitted by June, the company told the Central government during a discussion on obtaining the WHO s authorisation for emergency use listing for Covaxin, sources said.
The company is confident about obtaining WHO s emergency use listing.
Sources also said that Covaxin received regulatory approval in 11 countries and interest from 11 companies in seven countries for technology transfer and production.
Pfizer said discussions with the centre - to roll out its vaccine in India - were ongoing (File)
New Delhi:
States scrambling to buy Covid vaccines directly from foreign manufacturers - to boost what they say is insufficient supply from the centre - seem to be running into a roadblock in some cases, with at least two pharmaceutical giants refusing to sell to them.
American companies Pfizer and Moderna have turned down requests to supply Delhi and Punjab with their vaccines. Both cited official policy and said they would only deal with the centre. Pfizer will supply COVID-19 vaccines only to central governments for deployment in national immunisation programmes. Allocation of doses and implementation plan within a country is a decision for local governments based on relevant health authority guidelines, the company said.